Key Highlights: Fast-Tracking Clinical Readiness: The agreement enables process and analytical development activities required to advance Nimvec™ AM510 for Type 1 Diabetes toward cGMP manufacturing and first-in-human clinical trials Strengthening the Amarna–NorthX Biologics Alliance: This milestone marks a significant step forward in the companies’ shared vision to bring innovative gene therapies to patients with unmet medical needs Amarna Therapeutics, (“Amarna” or “the Company”), a privately

July 09, 2025 -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented “Bezisterim Epigenetic Effects on Aging and Neurodegeneration” at the 7th World Aging and Rejuvenation Conference (ARC-2025) taking place in Vienna, Austria, July 9th –10th, 2025. Unlike historical approach to Alzheimer’s Disease (AD) treatment that focuses on

Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs. The market leading epidermal growth factor receptor (“EGFR”) and anaplastic lymphoma kinase (“ALK”) inhibitors for the treatment of non-small cell lung cancer (“NSCLC”) are substrates of the Cytochrome P450 (“CYP”) enzyme CYP3A, and therefore their combination with drugs that are strong inducers of

July 09, 2025 -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced the close of a $93,390,000 million financing. The proceeds from this round will be used to advance CoRegen’s chemistry, manufacturing, and controls (CMC) development, initiate a Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program in patients with various solid-

- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill that aims to drive longer-lasting benefit by outpacing resistance mechanisms that cause cancer drugs to stop working - - Additional patent applications pending for atebimetinib directed to compounds, pharmaceutical compositions, and methods of use with expiration expected into

Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval July 08, 2025 -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication of two peer-reviewed articles highlighting nonclinica

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits July 09, 2025 -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced the initiation of a Phase 1 single-ascending dose/multiple-asce

July 07, 2025 -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical solution, a next-generation formulation in development for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The UTOPIA trial enr

July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the next USD 39 million to Basilea to continue to advance the development

July 07, 2025 -- Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its multi-regional, randomized, double-blind, placebo-controlled Phase 2b study of sorafenib (SORA) with or without YIV-906 in advanced hepatocellular carcinoma (HCC) patients with chronic hepatitis B (HBV+). Results were highlighted in an American Society of Clinical Oncology (ASCO) Annual Meeting (May 30-June 3) abstract and presented at the European Society for